European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

by Marie Weil
January 10, 2023
A A
Share on LinkedinShare on Twitter

Acquisition to access global rights to baxdrostat, a novel aldosterone synthase inhibitor in development for blood pressure lowering

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.

The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension.

Baxdrostat represents a potentially leading next-generation ASI as it is highly selective for aldosterone synthase and spares the cortisol pathway in humans1. The opportunity also brings the potential for combination with Farxiga and complements AstraZeneca’s strategy to provide added benefit across cardiorenal diseases, where there is a high unmet medical need.

Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, AstraZeneca, said: “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat. Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”

Marc de Garidel, CEO CinCor, said: “We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved. CinCor is committed to ensuring a smooth transition of the development responsibilities to AstraZeneca once the acquisition is consummated. Thank you to all who have played, and will continue to play, essential roles in developing and evaluating baxdrostat as a potential novel treatment for cardiorenal diseases.”

Tags: < Invest

Related Industries

Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

January 25, 2023
Health


Philips and Masimo expand partnership to improve telehealth for patients and clinicians around the world

January 19, 2023
Health

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 10, 2023
Health

Boehringer Ingelheim announces appointments to Board of Managing Directors

December 21, 2022
Health

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

December 20, 2022
Health

Roche changes in the Board of Directors and the Corporate Executive Committee

December 13, 2022

NXP Introduces Advanced Automotive Radar One-Chip Family for Next-Gen ADAS and Autonomous Driving Systems

January 6, 2023

...

Siemens and Skyway collaborate to develop infrastructure to pave way for Vertiports

January 27, 2023

...

A.P. Moller – Maersk announces new executive leadership team

January 11, 2023

...

New Head of Public Relations, Media and Communications EMEA and Marketing Replacement Tires Germany at Continental

January 12, 2023

...


Philips and Masimo expand partnership to improve telehealth for patients and clinicians around the world

January 19, 2023

...

IHG Hotels & Resorts opens global headquarters in Windsor

January 12, 2023

...

Covestro and LANXESS cooperate to produce more sustainable raw materials with reduced CO2 footprint

January 20, 2023

...

Spark collaborates with Ericsson and Red Hat for 5G Standalone trial

January 26, 2023

...

A.P. Moller – Maersk and DP World enter a long-term partnership to decarbonise logistics and improve customer services

January 14, 2023

...

Das neue ZF-Vorstandsteam (von links nach rechts): Michael Frick, Dr. Martin Fischer, Vorstandsvorsitzender Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula und Stephan von Schuckmann.
//
ZF’s newly formed Board of Management team (from left to right): Michael Frick, Dr. Martin Fischer, CEO Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula and Stephan von Schuckmann.

ZF Kicks Off 2023 With New Executive Management Team

January 13, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist